Shibin Zhou
Auto-generated profile, based on publicly available information

Shibin Zhou

Ludwig Center and Lustgarten Laboratory, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2017 in Science
Verified
Journal Article
Closed access
PDF file
DLDung T. Le
Dung T. Le
JDJennifer N. Durham
Jennifer N. Durham
KSKellie N. Smith
Kellie N. Smith
HWHao Wang
Hao Wang
BBBjarne R. Bartlett
Bjarne R. Bartlett
LDLuis A. Diaz
Luis A. Diaz
Predicting responses to immunotherapy: Colon cancers with loss-of-function mutations in the mismatch repair (MMR) pathway have favorable responses to PD-1 blockade immunotherapy. In a phase 2 clinical trial, Le et al. showed that treatment success is not just limited to colon cancer (see the Perspective by Goswami and Sharma). They found that a wide range of different cancer types with MMR deficiency also responded to PD-1 blockade. The trial included some patients with pancreatic cancer, which is one of the deadliest forms of cancer. The clinical trial is still ongoing, and around 20% of patients have so far achieved a complete response. MMR deficiency appears to be a biomarker for predicting successful treatment outcomes for several solid tumors and indicates a new therapeutic option for patients harboring MMR-deficient cancers. Science , this issue p. 409 ; see also p. 358

23 February 2018 in Science
Verified
Journal Article
Open access
PDF file
JCJoshua D. Cohen
Joshua D. Cohen
LLLu Li
Lu Li
YWYuxuan Wang
Yuxuan Wang
CTChristopher Thoburn
Christopher Thoburn
BABahman Afsari
Bahman Afsari
NPNickolas Papadopoulos
Nickolas Papadopoulos
SEEK and you may find cancer earlier: Many cancers can be cured by surgery and/or systemic therapies when detected before they have metastasized. This clinical reality, coupled with the growing appreciation that cancer's rapid genetic evolution limits its response to drugs, have fueled interest in methodologies for earlier detection of the disease. Cohen et al. developed a noninvasive blood test, called CancerSEEK that can detect eight common human cancer types (see the Perspective by Kalinich and Haber). The test assesses eight circulating protein biomarkers and tumor-specific mutations in circulating DNA. In a study of 1000 patients previously diagnosed with cancer and 850 healthy control individuals, CancerSEEK detected cancer with a sensitivity of 69 to 98% (depending on cancer type) and 99% specificity. Science , this issue p. 926 ; see also p. 866

7 November 2018 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
SZShibin Zhou
Shibin Zhou
CGClaudia Gravekamp
Claudia Gravekamp
DBDavid Bermudes
David Bermudes
KLKe Liu
Ke Liu

21 July 2021 in Nature
Verified
Journal Article
Open access
PDF file
JCJustina X. Caushi
Justina X. Caushi
JZJiajia Zhang
Jiajia Zhang
ZJZhicheng Ji
Zhicheng Ji
AVAjay Vaghasia
Ajay Vaghasia
BZBoyang Zhang
Boyang Zhang
KSKellie N. Smith
Kellie N. Smith
PD-1 blockade unleashes CD8 T cells1, including those specific for mutation-associated neoantigens (MANA), but factors in the tumour microenvironment can inhibit these T cell responses. Single-cell transcriptomics have revealed global T cell dysfunction programs in tumour-infiltrating lymphocytes (TIL). However, the majority of TIL do not recognize tumour antigens2, and little is known about transcriptional programs of MANA-specific TIL. Here, we identify MANA-specific T cell clones using the MANA functional expansion of specific T cells assay3in neoadjuvant anti-PD-1-treated non-small cell lung cancers (NSCLC). We use their T cell receptors as a ‘barcode’ to track and analyse their transcriptional programs in the tumour microenvironment using coupled single-cell RNA sequencing and T cell receptor sequencing. We find both MANA- and virus-specific clones in TIL, regardless of response, and MANA-, influenza- and Epstein–Barr virus-specific TIL each have unique transcriptional programs. Despite exposure to cognate antigen, MANA-specific TIL express an incompletely activated cytolytic program. MANA-specific CD8 T cells have hallmark transcriptional programs of tissue-resident memory (TRM) cells, but low levels of interleukin-7 receptor (IL-7R) and are functionally less responsive to interleukin-7 (IL-7) compared with influenza-specific TRM cells. Compared with those from responding tumours, MANA-specific clones from non-responding tumours express T cell receptors with markedly lower ligand-dependent signalling, are largely confined to HOBIThighTRM subsets, and coordinately upregulate checkpoints, killer inhibitory receptors and inhibitors of T cell activation. These findings provide important insights for overcoming resistance to PD-1 blockade.

3 July 2020 in Science
Verified
Journal Article
Closed access
PDF file
ALAnne Marie Lennon
Anne Marie Lennon
Adam H BuchananAdam H Buchanan
Adam H Buchanan
IKIsaac Kinde
Isaac Kinde
AWAndrew Warren
Andrew Warren
AHAshley Honushefsky
Ashley Honushefsky
NPNickolas Papadopoulos
Nickolas Papadopoulos
A real-time trial of a cancer blood test: Cancers diagnosed early are often more responsive to treatment. Blood tests that detect molecular markers of cancer have successfully identified individuals already known to have the disease. Lennon et al. conducted an exploratory study that more closely reflects the way in which such blood tests would be used in the future. They evaluated the feasibility and safety of incorporating a multicancer blood test into the routine clinical care of 10,000 women with no history of cancer. Over a 12-month period, the blood test detected 26 cancers of different types. A combination of the blood test and positron emission tomography–computed tomography (PET-CT) imaging led to surgical removal of nine of these cancers. Use of the blood test did not result in a large number of futile follow-up procedures. Science , this issue p. eabb9601

28 July 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
KKKiBem Kim
KiBem Kim
ASAndrew D. Skora
Andrew D. Skora
ZLZhaobo Li
Zhaobo Li
QLQiang Liu
Qiang Liu
ATAda J. Tam
Ada J. Tam
SZShibin Zhou
Shibin Zhou
Significance: Recent clinical trials have shown highly promising responses in a subset of patients treated with immune checkpoint inhibitory anti–programmed cell death-1, anti–programmed cell death ligand-1, and anti–cytotoxic T-lymphocyte-associated antigen-4 antibodies, but the majority of patients in these trials remained unresponsive. Our results show that elevated myeloid-derived suppressor cells(MDSCs) are responsible for the resistance and that elimination of MDSCs can lead to cures of experimental, metastatic tumors.